Schedule of Segment Reporting Information, by Segment |
Further, the following represents information about segment revenue, segment loss and significant segment expenses (in thousands): | | | | | | | | | | | | | Three Months Ended March 31, | | 2025 | | 2024 | Collaboration revenue | $ | 5,952 | | | $ | 5,050 | | Less: | | | | Research and development: | | | | Personnel expenses | 6,344 | | | 6,287 | | FHD-286 | 991 | | | 3,526 | | Lilly partnered programs | 4,625 | | | 3,886 | | Proprietary programs | 3,447 | | | 5,286 | | Research and development operating and administrative costs | 1,667 | | | 1,625 | | General and administrative: | | | | Personnel expenses | 2,927 | | | 2,543 | | External expenses | 2,072 | | | 2,574 | | Facilities and IT related expenses, net of sublease income | 1,877 | | | 2,715 | | Other expenses(1) | 3,528 | | | 4,063 | | | | | | Plus: | | | | Interest income | 2,692 | | | 2,439 | | Net loss | $ | (18,834) | | | $ | (25,016) | |
(1) Inclusive of $2.7 million and $3.2 million of stock compensation expense for the three months ended March 31, 2025 and 2024, respectively; $0.8 million of depreciation and amortization expense for the three months ended March 31, 2025 and 2024
|